Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Data made public by the Centers for Medicare & Medicaid Services shows that drug and device makers made nearly $8.2 billion in payments to U.S. physicians and teaching hospitals in the last year. Since 2013, CMS has been tracking physician payments as part of the Affordable Care Act.

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Dr. Sharad Lakhanpal, President of the American College of Rheumatology has responded to the Senate's proposed changes to healthcare coverage in the USA.

Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017. 

Dr. Jack Cush reviews his approach to attending and getting the most out of ACR or EULAR Congress meetings.

Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.

The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop consensus-based guidelines for perioperative management of antirheumatic therapies for patients with rheumatic diseases who plan to undergo total joint replacement.

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.

Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.

Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas.

A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab, in patients with active psoriatic arthritis.  

Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ).

Young patients with systemic lupus erythematosus (SLE) get diagnosed before they have completed their families. About 30 or 40 years ago, most rheumatologists were not recommending pregnancy for their lupus patients. However, in recent times, outcomes have considerably improved.

Dr. Jack Cush reviews some of the highlights from the past week at EULAR 2017 - June 16, 2017.

Follow RheumNow's expanded coverage from EULAR 2017 in Madrid.

The heat was on at EULAR 2017 for busy presenters and attendees navigating the 104F degree temperatures at the indoor/outdoor IFEMA Convention center in Madrid.

Day 2 (Thursday) were big days for gout, drug safety, psoriatic arthritis and spondyloarthritis. 

Today I came across two interesting sessions given by Gossec Laure from France and William Dixon from the United Kingdom. They talked about digital epidemiology in this changing world, as there are approximately 15 billion connected devices and more than 80,000 medical apps.

Pegloticase is indicated for treatment of patients with refractory gout. One major issue hampering the comfort levels of rheumatologists to use this agent is the boxed warning in the package insert regarding the documentation of anaphylaxis with the infusions.  It is well known that treatment with pegloticase is associated with the development of anti-drug antibodies, which are believed to belie these reactions.

Lxekizumab performs well in TNF nonresponders phase 3 trial.

With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies, the question of efficacy and safety in different clinical scenarios arises. The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks.

Normal
0




false
false
false

EN-US
X-NONE
X-NONE


























































































































































































































































































































































































































/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin:0cm;
mso-para-margin-bottom:.0001pt;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:Arial;
color:black;}